# US 6,727,064 B2 · Antisense oligonucleotide modulation of STAT3 expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,064 B2
- Document ID: US6727064B2
- Status: Granted
- Kind: B2
- Application number: 09/758,881
- Filed: 2001-01-11
- Published: 2001-10-11
- Granted: 2004-04-27
- Earliest claimed: 1999-04-08
- Assignees: Isis Pharmaceuticals, Inc.
- Inventors: James G. Karras
- Web page: https://patentgrep.com/patent/US6727064B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.

## Claims

### Claim 1

An antisense compound 20 to 30 nucleobases in length targeted to nucleobases 637-656 and 1669-1688 of human STAT3 (SEQ ID NO: 1), wherein said antisense compound inhibits the expression of human STAT3.

### Claim 2 (depends on 1)

The antisense compound of claim 1 which is an antisense oligonucleotide.

### Claim 3 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 4 (depends on 3)

The antisense compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

### Claim 5 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

### Claim 6 (depends on 5)

The antisense compound of claim 5 wherein the modified sugar moiety is a 2′-O-methoxyethyl moiety.

### Claim 7 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

### Claim 8 (depends on 7)

The antisense compound of claim 7 wherein modified nucleobase is a 5-methyl cytosine.

### Claim 9 (depends on 1)

The antisense compound of claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

### Claim 10 (depends on 1)

A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 11 (depends on 10)

The composition of claim 10 further comprising a colloidal dispersion system.

### Claim 12 (depends on 10)

The composition of claim 10 wherein the antisense compound is an antisense oligonucleotide.

### Claim 13 (depends on 1)

A method of inhibiting the expression of STAT3 in human cells or tissues comprising contacting said cells or tissue in vitro or ex vitro with the antisense compound of claim 1 so that expression of STAT3 is inhibited.

### Claim 14 (depends on 1)

A method of inducing apoptosis in a cell comprising contacting a cell in vitro or ex vivo with the antisense compound of claim 1 so that apoptosis is induced.

### Claim 15 (depends on 14)

The method of claim 14 wherein said apoptosis is Fas-mediated.
